Table 3.
Odds of ADT and AS for prostate cancer by patient characteristics
| N | ADT |
AS |
|||||
|---|---|---|---|---|---|---|---|
| n (row %) | OR* (95% CI) | P-value | n (row %) | OR* (95% CI) | P-value | ||
| Age (ye) | |||||||
| ≤60 | 445 | 19 (4.3) | 1.0 | Ref | 29 (6.5) | 1.0 | Ref |
| >60 to ≤70 | 457 | 38 (8.3) | 1.4 (0.69-2.7) | .376 | 68 (14.9) | 3.3 (2.0-5.5) | <.0001 |
| >70 | 186 | 48 (25.8) | 3.8 (1.8-7.9) | .001 | 44 (23.7) | 7.0 (3.7-13.1) | <.0001 |
| Race/ethnicity | |||||||
| White | 453 | 13 (2.9) | 1.0 | Ref | 44 (9.7) | 1.0 | Ref |
| Black | 420 | 63 (15.0) | 3.3 (1.5-6.9) | .002 | 71 (16.9) | 1.9 (1.2-3.1) | .011 |
| Hispanic/Latino | 130 | 19 (14.6) | 3.7 (0.79-17.6) | .098 | 10 (7.7) | 0.72 (0.15-3.4) | .673 |
| Other | 85 | 10 (11.8) | 3.3 (0.92-11.5) | .066 | 16 (18.8) | 1.3 (0.59-3.1) | .487 |
| Primary language | |||||||
| English | 847 | 70 (8.3) | 1.0 | Ref | 98 (11.6) | 1.0 | Ref |
| Spanish | 101 | 15 (14.9) | 1.4 (0.29-6.9) | .672 | 8 (7.9) | 0.97 (0.18-5.3) | .968 |
| Haitian Creole | 71 | 12 (16.9) | 0.84 (0.33-2.1) | .707 | 20 (28.2) | 2.4 (1.2-4.8) | .017 |
| Other | 69 | 8 (11.6) | 0.75 (0.21-2.7) | .656 | 15 (21.7) | 1.8 (0.78-4.3) | .169 |
| Insurance status | |||||||
| Commercial/Private | 403 | 16 (4.0) | 1.0 | Ref | 37 (9.2) | 1.0 | Ref |
| Medicaid/Free Care | 278 | 32 (11.5) | 1.5 (0.68-3.3) | .315 | 39 (14.0) | 1.5 (0.82-2.6) | .198 |
| Medicare/Military | 407 | 57 (14.0) | 1.5 (0.71-3.0) | .309 | 65 (16.0) | 1.5 (0.89-2.4) | .136 |
| Marital status | |||||||
| Married | 643 | 49 (7.6) | 1.0 | Ref | 80 (12.4) | 1.0 | Ref |
| Single | 284 | 34 (12.0) | 1.1 (0.62-2.0) | .717 | 39 (13.7) | 1.4 (0.89-2.3) | .136 |
| Other | 161 | 22 (13.7) | 1.9 (0.92-3.7) | .084 | 22 (13.7) | 1.1 (0.64-2.0) | .671 |
| AJCC | |||||||
| Stage II | 985 | 88 (8.9) | 1.0 | Ref | 141 (14.3) | 1.0 | Ref |
| Stage III | 103 | 17 (16.5) | 0.86 (0.43-1.7) | .665 | 0 (0.0) | — | — |
| Risk category | |||||||
| Low | 503 | 1 (0.20) | 1.0 | Ref | 106 (21.1) | 1.0 | Ref |
| Intermediate | 411 | 25 (6.1) | 25.8 (3.5-192.6) | .002 | 27 (6.6) | 0.19 (0.11-0.31) | <.0001 |
| High | 174 | 79 (45.4) | 289.4 (39.2 to >999.0) | < .0001 | 8 (4.6) | 0.08 (0.04-0.18) | <.0001 |
ADT, androgen deprivation therapy; AJCC, American Joint Committee on Cancer; AS, active surveillance; CI, confidence interval; OR, odds ratio; Ref, reference.
*
OR calculated using multiple logistic regression adjusting for all patient characteristics.